Developer docs
API playgroundTry for free, no card

Search company profiles

T1D Exchange

Full company profile

uuid000emb7

Namestring
T1D Exchange
Legal namestring
T1D Exchange
Websiteurl
t1dexchange.org
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
diabetes patient registry, clinical research services, real-world evidence, quality improvement collaborative, healthcare data platform
Industry3 codes
PRIMARYHLAKADAB
Type 1 Diabetes Care
SECONDARYHLACABAB
HIE Platforms & Network Services (Community/Regional/National)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLACABAI
Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
NAICS code3 codes
  • Health Care and Social Assistance62
  • Other Ambulatory Health Care Services6219
  • Ambulatory Health Care Services621
SIC code1 code
  • Services-Health Services8000
Product category
Diabetes Clinical Research and Quality Improvement Services
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Research Grants and Funding
TypeLicensing Royalties
Description

As a nonprofit organization, T1D Exchange relies primarily on grant funding from organizations such as The Leona M. and Harry B. Helmsley Charitable Trust to fund the T1DX-QI and other initiatives.

t1dexchange.org
2Custom Research Services
TypeProfessional Services
Description

T1D Exchange collaborates with pharmaceutical companies and academic partners to conduct custom research studies, providing study design, data collection, analysis, and reporting services in exchange for research funding.

t1dexchange.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1T1D Exchange Registry
Description

A long-term research study following people with T1D, with over 23,000 individuals participating.

t1dexchange.org
+2 more records
Core offering1 text field

T1D Exchange operates a long-term patient Registry enrolling people with type 1 diabetes to share lived experiences through surveys and participate in research, and the T1DX-QI quality improvement collaborative, a network of 60+ endocrinology centers sharing de-identified EHR data. It sells custom research services and study recruitment to pharmaceutical and academic partners, and produces clinical resources such as Change Packages, the Beta Cell Preservation Framework, and the HEAL health equity program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Children who started CGM within first six months after T1D diagnosis had lower A1Cs three years later compared to those who started later
+3 more records
Product overview1 text field

T1D Exchange is a nonprofit organization operating a platform of interconnected research and quality improvement products focused on type 1 diabetes. The core offerings include the T1D Exchange Registry (a long-term research study with 23,000+ participants), the T1DX-QI Portal (a secure data platform for the Quality Improvement Collaborative network of 60+ clinics), and Study Recruitment and Custom Research services for academic and industry partners. Additional products include the HEAL health equity program, Change Packages (clinical resources), Beta Cell Preservation framework, and engagement features like Question of the Day. These offerings work together to facilitate research and drive improvements in care for people with type 1 diabetes through real-world evidence generation and collaborative learning across a nationwide network of endocrine clinics.

Product and service8 records
1T1D Exchange Registry
CategoryPatient Registry Platform
Description

A long-term research study that follows people with type 1 diabetes over time, with over 23,000 individuals participating. Registry participants share perspectives through surveys and can take part in additional research opportunities.

2T1DX-QI Portal
CategoryClinical Data Platform
Description

A secure data platform that facilitates collaboration among T1DX-QI clinics using real-world EHR-based data to improve health outcomes among people living with type 1 diabetes.

3T1D Exchange Quality Improvement Collaborative (T1DX-QI)
CategoryClinical Quality Improvement Collaborative
Description

A collaborative network bringing together over 60 pediatric and adult endocrinology centers across the United States that care for over ~100,000 individuals with type 1 diabetes. Members share data via the T1D Quality Improvement platform to track baselines, outcomes, and improve care.

4Study Recruitment Services
CategoryResearch Services
Description

Connects researchers with engaged individuals and research-ready networks including the 23,000+ Registry participants and 75,000+ people impacted by T1D to accelerate study recruitment. Has supported 70+ studies.

5Custom Research Services
CategoryResearch Services
Description

Collaborative research design and execution services including study design, data collection, analysis, and reporting grounded in real-world experience from the T1D community, provided to pharmaceutical companies and academic partners under research agreements.

6HEAL Program (Health Equity Advancement Lab)
CategoryHealth Equity Program
Description

A health equity improvement initiative that uses real-world data and collaboration to improve outcomes for people living with diabetes by addressing disparities in diabetes care.

7Beta Cell Preservation Framework
CategoryClinical Framework
Description

A clinical and implementation framework from the T1DX-QI Beta Cell Preservation Working Group providing screening frameworks, staging protocols, and disease-modifying therapy workflow guidance.

8Change Packages
CategoryClinical Resources
Description

Actionable resources documenting proven strategies and interventions from T1DX-QI centers including High-Risk T1D care, CGM Equity, Depression Screening, Access to Clinical Care, and Building QI Capacity.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in Campamento Familiar en Español, a Spanish-language diabetes camp program in partnership with UCSF to support Latinx families affected by T1D.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Jaeb Center for Health Research
TypeDirect peer
Description

Originally led the founding of the T1D Exchange Clinic Registry and Network in 2010. Operates a similar model of disease-specific patient registries and clinical research coordination, particularly in diabetes and ophthalmology, making it the closest operational analogue.

TypeDirect peer
Description

The largest T1D-focused nonprofit, funding research and advocacy globally. Comparable as a T1D-specific nonprofit that convenes researchers, clinicians, and patients, and overlapping with T1D Exchange in research funding and community engagement.

TypeDirect peer
Description

T1D-focused nonprofit operating programs, community, and grant-making with a digital-first model. Comparable as a T1D nonprofit that builds community engagement surfaces T1D Exchange leverages for research participation.

TypeDirect peer
Description

Operates the Cystic Fibrosis Foundation Patient Registry, one of the longest-running disease-specific registries, alongside a care center network and quality improvement program. Highly comparable as a disease-specific nonprofit that combines a patient registry, accredited care network, and QI collaborative to drive research and outcomes.

TypeDirect peer
Description

Diabetes-focused nonprofit producing patient education, research coverage, and community programs. Overlaps with T1D Exchange on patient engagement, content, and surfacing real-world T1D experience to researchers and industry.

TypeEmerging player
Description

Health system-owned real-world data platform aggregating de-identified EHR data for research. Comparable in providing EHR-based real-world evidence to pharma, but operates across all conditions rather than T1D-specific.

7Tempus
TypeBroad incumbent
Description

AI-enabled precision medicine company with large-scale clinical and molecular data across multiple disease areas. Comparable as a real-world evidence and AI-driven research platform serving pharma, though broader in scope than T1D Exchange.

TypeBroad incumbent
Description

Global clinical research and real-world evidence leader. Overlaps with T1D Exchange on clinical trial recruitment support and real-world data analytics for pharma, though at vastly greater scale and across all therapeutic areas.

TypeBroad incumbent
Description

Real-world evidence platform focused on oncology, built from EHR data. Operates a similar model of aggregating de-identified clinical data from provider networks to support pharma research and regulatory submissions.

TypeEmerging player
Description

Diabetes data nonprofit offering a platform for visualizing data from CGM, insulin pumps, and CGMs. A listed T1D Exchange partner; comparable as a diabetes-focused nonprofit building data infrastructure used by people with T1D and the research community.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles23 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

T1D Exchange

Diabetes Clinical Research and Quality Improvement Servicest1dexchange.org

T1D Exchange firmographics

Firmographics
Name
T1D Exchange
Legal name
T1D Exchange
Website
https://t1dexchange.org
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

T1D Exchange industry classification

Industry
Product category
Diabetes Clinical Research and Quality Improvement Services
NAICS
Health Care and Social Assistance (62), Other Ambulatory Health Care Services (6219), Ambulatory Health Care Services (621)
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAKADAB
Type 1 Diabetes Care
SECONDARYHLACABAB
HIE Platforms & Network Services (Community/Regional/National)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability
SECONDARYHLACABAI
Clinical Document & Data Exchange (C-CDA, CCD, Direct Messaging)
Healthcare & Life Sciences/Digital Health & Health IT/Health Information Exchange (HIE) & Interoperability

Keywords

  • Diabetes patient registry
  • Clinical research services
  • Real-world evidence
  • Quality improvement collaborative
  • Healthcare data platform

Where T1D Exchange is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

T1D Exchange business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Research Grants and Funding: As a nonprofit organization, T1D Exchange relies primarily on grant funding from organizations such as The Leona M. and Harry B. Helmsley Charitable Trust to fund the T1DX-QI and other initiatives.
  2. Custom Research Services: T1D Exchange collaborates with pharmaceutical companies and academic partners to conduct custom research studies, providing study design, data collection, analysis, and reporting services in exchange for research funding.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

T1D Exchange product offering

Product offering

Core offering

T1D Exchange operates a long-term patient Registry enrolling people with type 1 diabetes to share lived experiences through surveys and participate in research, and the T1DX-QI quality improvement collaborative, a network of 60+ endocrinology centers sharing de-identified EHR data. It sells custom research services and study recruitment to pharmaceutical and academic partners, and produces clinical resources such as Change Packages, the Beta Cell Preservation Framework, and the HEAL health equity program.

Product overview

T1D Exchange is a nonprofit organization operating a platform of interconnected research and quality improvement products focused on type 1 diabetes. The core offerings include the T1D Exchange Registry (a long-term research study with 23,000+ participants), the T1DX-QI Portal (a secure data platform for the Quality Improvement Collaborative network of 60+ clinics), and Study Recruitment and Custom Research services for academic and industry partners. Additional products include the HEAL health equity program, Change Packages (clinical resources), Beta Cell Preservation framework, and engagement features like Question of the Day. These offerings work together to facilitate research and drive improvements in care for people with type 1 diabetes through real-world evidence generation and collaborative learning across a nationwide network of endocrine clinics.

Differentiator

Problem solved

Functional benefit

Brands

  • T1D Exchange Registry: A long-term research study following people with T1D, with over 23,000 individuals participating.
  • T1DX-QI (T1D Exchange Quality Improvement Collaborative)
  • HEAL (Health Equity Improvement Lab)

Products and services

  • T1D Exchange Registry A long-term research study that follows people with type 1 diabetes over time, with over 23,000 individuals participating. Registry participants share perspectives through surveys and can take part in additional research opportunities.
  • T1DX-QI Portal A secure data platform that facilitates collaboration among T1DX-QI clinics using real-world EHR-based data to improve health outcomes among people living with type 1 diabetes.
  • T1D Exchange Quality Improvement Collaborative (T1DX-QI) A collaborative network bringing together over 60 pediatric and adult endocrinology centers across the United States that care for over ~100,000 individuals with type 1 diabetes. Members share data via the T1D Quality Improvement platform to track baselines, outcomes, and improve care.
  • Study Recruitment Services Connects researchers with engaged individuals and research-ready networks including the 23,000+ Registry participants and 75,000+ people impacted by T1D to accelerate study recruitment. Has supported 70+ studies.
  • Custom Research Services Collaborative research design and execution services including study design, data collection, analysis, and reporting grounded in real-world experience from the T1D community, provided to pharmaceutical companies and academic partners under research agreements.
  • HEAL Program (Health Equity Advancement Lab) A health equity improvement initiative that uses real-world data and collaboration to improve outcomes for people living with diabetes by addressing disparities in diabetes care.
  • Beta Cell Preservation Framework A clinical and implementation framework from the T1DX-QI Beta Cell Preservation Working Group providing screening frameworks, staging protocols, and disease-modifying therapy workflow guidance.
  • Change Packages Actionable resources documenting proven strategies and interventions from T1DX-QI centers including High-Risk T1D care, CGM Equity, Depression Screening, Access to Clinical Care, and Building QI Capacity.

Quantifiable outcome

  • Children who started CGM within first six months after T1D diagnosis had lower A1Cs three years later compared to those who started later
  • +3 more outcomes

Companies that use T1D Exchange

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

T1D Exchange technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

T1D Exchange partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DYF (Diabetes Youth Families)minorStrategic or Co-development PartnerPartner in Campamento Familiar en Español, a Spanish-language diabetes camp program in partnership with UCSF to support Latinx families affected by T1D.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

T1D Exchange competitors and assessment

Company assessment

Direct peers

  • Jaeb Center for Health Research: Originally led the founding of the T1D Exchange Clinic Registry and Network in 2010. Operates a similar model of disease-specific patient registries and clinical research coordination, particularly in diabetes and ophthalmology, making it the closest operational analogue.
  • JDRF (Breakthrough T1D): The largest T1D-focused nonprofit, funding research and advocacy globally. Comparable as a T1D-specific nonprofit that convenes researchers, clinicians, and patients, and overlapping with T1D Exchange in research funding and community engagement.
  • Beyond Type 1: T1D-focused nonprofit operating programs, community, and grant-making with a digital-first model. Comparable as a T1D nonprofit that builds community engagement surfaces T1D Exchange leverages for research participation.
  • Cystic Fibrosis Foundation: Operates the Cystic Fibrosis Foundation Patient Registry, one of the longest-running disease-specific registries, alongside a care center network and quality improvement program. Highly comparable as a disease-specific nonprofit that combines a patient registry, accredited care network, and QI collaborative to drive research and outcomes.
  • diaTribe Foundation: Diabetes-focused nonprofit producing patient education, research coverage, and community programs. Overlaps with T1D Exchange on patient engagement, content, and surfacing real-world T1D experience to researchers and industry.

Emerging players

  • Truveta: Health system-owned real-world data platform aggregating de-identified EHR data for research. Comparable in providing EHR-based real-world evidence to pharma, but operates across all conditions rather than T1D-specific.
  • Tidepool: Diabetes data nonprofit offering a platform for visualizing data from CGM, insulin pumps, and CGMs. A listed T1D Exchange partner; comparable as a diabetes-focused nonprofit building data infrastructure used by people with T1D and the research community.

Broad incumbents

  • Tempus: AI-enabled precision medicine company with large-scale clinical and molecular data across multiple disease areas. Comparable as a real-world evidence and AI-driven research platform serving pharma, though broader in scope than T1D Exchange.
  • IQVIA: Global clinical research and real-world evidence leader. Overlaps with T1D Exchange on clinical trial recruitment support and real-world data analytics for pharma, though at vastly greater scale and across all therapeutic areas.
  • Flatiron Health: Real-world evidence platform focused on oncology, built from EHR data. Operates a similar model of aggregating de-identified clinical data from provider networks to support pharma research and regulatory submissions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

T1D Exchange social profiles

Digital presence

T1D Exchange financial estimates

Financial estimate

Revenue estimate

Valuation estimate

T1D Exchange leadership team

Management profile

Number of profiles

Profiles23 records

T1D Exchange funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

T1D Exchange M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about T1D Exchange

What does T1D Exchange do?

T1D Exchange operates a long-term patient Registry enrolling people with type 1 diabetes to share lived experiences through surveys and participate in research, and the T1DX-QI quality improvement collaborative, a network of 60+ endocrinology centers sharing de-identified EHR data. It sells custom research services and study recruitment to pharmaceutical and academic partners, and produces clinical resources such as Change Packages, the Beta Cell Preservation Framework, and the HEAL health equity program.

Is T1D Exchange a public or private company?

T1D Exchange is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was T1D Exchange founded?

T1D Exchange was founded in 2016. It employs 51 to 100 people.

Where is T1D Exchange based?

T1D Exchange is headquartered in Boston, United States, in the North America region.

How does T1D Exchange make money?

Two revenue lines are on record. Research Grants and Funding is the primary driver. The others are custom Research Services.

Who are T1D Exchange's main competitors?

Direct peers on record are Jaeb Center for Health Research, JDRF (Breakthrough T1D), Beyond Type 1, Cystic Fibrosis Foundation and diaTribe Foundation. Emerging players are Truveta and Tidepool. Broad incumbents are Tempus, IQVIA and Flatiron Health.

Does T1D Exchange have an API?

No public API is recorded for T1D Exchange.

What industry is T1D Exchange in?

T1D Exchange's product category is Diabetes Clinical Research and Quality Improvement Services. Its primary akta.pro industry code is HLAKADAB, Type 1 Diabetes Care, with a secondary code of HLACABAB, HIE Platforms & Network Services (Community/Regional/National). Its NAICS code is 62 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TmcnetT1D Exchange Announces 21 Real-World Data Presentations at the American Diabetes Association (ADA) 84th Scientific SessionsT1D Exchange announced 21 real-world data presentations at the ADA 84th Scientific Sessions in Orlando, covering quality improvement, GLP-1 use, and CGM characteristics. The organization also launched a new diabetes equity conference in Chicago. The presentations draw from its Quality Improvement Collaborative and patient registry.PR NewswireT1D Exchange Announces 20 Upcoming Presentations at the American Diabetes Association (ADA) 83rd Scientific SessionsT1D Exchange, a nonprofit organization focused on type 1 diabetes research, announced that its researchers will present 20 studies at the American Diabetes Association 83rd Scientific Sessions in San Diego, California from June 23-26, 2023. The presentations include three oral presentations, two panel discussions, and 15 poster presentations covering topics such as continuous glucose monitoring, racial equity in diabetes care, and LGBTQ+ inclusiveness. One oral presentation, on CGM initiation associated with lower HbA1c levels, received the ADA Presidents' Select Abstract of Distinction out of over a thousand submissions.PR NewswireT1D Exchange to Highlight New Real-World Findings Across 18 Presentations at the American Diabetes Association 82nd Scientific SessionsT1D Exchange, a nonprofit organization focused on type 1 diabetes research, announced it will present 18 studies (4 oral, 14 poster) at the American Diabetes Association 82nd Scientific Sessions in New Orleans from June 3–7, 2022. The research covers health equity issues in T1D care, including persistent racial and ethnic inequities in glycemic outcomes despite advances in treatments and technology. The organization also extended its partnership with Vertex Pharmaceuticals, continuing to support patient recruitment for the Phase 1/2 clinical trial of VX-880, an investigational T1D therapy.PR NewswireNew T1D Exchange Data at American Diabetes Association 81st Scientific Sessions Highlight Patient Care InequitiesT1D Exchange announced new real-world data from its Quality Improvement Collaborative and patient Registry being presented at the American Diabetes Association 81st Scientific Sessions, revealing disparities in technology use and glycemic outcomes among type 1 diabetes patients. The studies, analyzing data from over 21,000 patients across 40 clinics, found inequities including lower insulin pump use among non-Hispanic Black patients compared to non-Hispanic white patients, while also demonstrating that quality improvement programs correlate with improved A1c levels. The research reinforces the value of system-wide quality improvement initiatives and real-world patient data in addressing persisting care inequities for the 1.6 million people living with T1D in the U.S.PR NewswireMedtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with DiabetesMedtronic plc announced ongoing health equity initiatives for people of color living with diabetes, including a $1 million three-year sponsorship to the American Diabetes Association's Technology Access Project aimed at expanding access to diabetes technology regardless of gender, race, income, or location. The company also entered a partnership with T1D Exchange for a quality improvement pilot to determine baseline diabetes technology use rates among people of color and test interventions to increase adoption. Additionally, Medtronic is supporting an NIH-funded study using its insulin pump technology to improve glycemic control in African American youth with type 1 diabetes at Louisiana State University School of Medicine.Welcome to MedtronicMedtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with DiabetesMedtronic announced ongoing initiatives to address health equity for people of color with diabetes, including a $1 million sponsorship over three years to ADA's Technology Access Project. The company also partnered with T1D Exchange for a quality improvement pilot to improve technology adoption among underrepresented groups, with results expected in 2022.PR NewswireT1D Exchange Quality Improvement Collaborative (QIC) Reaches 25 Diabetes Centers Participating NationwideT1D Exchange, a nonprofit organization focused on type 1 diabetes research, announced that its Quality Improvement Collaborative (QIC) has expanded to 25 U.S. diabetes centers, more than doubling the number of participating clinics since the beginning of 2020. The QIC, launched as a pilot program with 10 centers in 2016, enables member clinics to share data through a QI portal and work toward American Diabetes Association glycemic management targets of A1c less than seven percent. QIC members will hold a virtual learning session in November to share insights and advance their quality improvement efforts.PR NewswireT1D Exchange Names Glooko as Data Management Partner in Quality Improvement CollaborativeGlooko and T1D Exchange announced on June 4, 2019 an agreement to use Glooko's diabetes management solution to incorporate anonymized device data into the T1D Exchange Quality Improvement Collaborative, a platform of 11 U.S. diabetes centers serving more than 30,000 people with type 1 diabetes. The deal enables de-identified data from blood glucose meters, insulin pumps, CGMs and smart pens to be transferred to the QIC platform, expanding outcome measures beyond A1c.GlobeNewswireT1D Exchange Names New Board MembersT1D Exchange added four new board members—David Walton, Gina Agiostratidou, Jack Collins, and Cristina Csimma—serving three-year terms. The additions aim to strengthen expertise in type 1 diabetes, financial management, and therapeutic development. The organization also recently launched a new website and announced a Tidepool study on continuous glucose monitoring.